Chronic Myeloid Leukemia in 2020

Overview

Journal Hemasphere

Publisher Wiley

Specialty Hematology

Date 2020 Nov 2

PMID 33134861

Citations 33

Authors

Rudiger Hehlmann

Affiliations

Soon will be listed here.

Abstract

New insights have emerged from maturing long-term academic and commercial clinical trials regarding optimum management of chronic myeloid leukemia (CML). Velocity of response has unexpectedly proved less important than hitherto thought, does not predict survival, and is of unclear relevance for treatment-free remission (TFR). Serious and cumulative toxicity has been observed with tyrosine kinase inhibitors that had been expected to replace imatinib. Generic imatinib has become cost-effective first-line treatment in chronic phase despite chronic low-grade side-effects in many patients. Earlier recognition of end-phase by genetic assessment might improve prospects for blast crisis (BC). TFR has become an important new treatment goal of CML. To reflect this new situation ELN has recently revised and updated its recommendations for treating CML. After a brief review of 175 years of CML history this review will focus on recent developments and on current evidence for treating CML in 2020.

Citing Articles

Investigating the role of non-synonymous variant D67N of ADGRE2 in chronic myeloid leukemia.

Afzal A, Jamshaid H, Badshah Y, Shabbir M, Trembley J, Zafar S BMC Cancer. 2024; 24(1):1354.

PMID: 39501172 PMC: 11536965. DOI: 10.1186/s12885-024-13108-6.

Asciminib in Advanced-Line Treatment of Chronic Myeloid Leukemia.

Shacham-Abulafia A, Volcheck Y, Ellis M, Shapira S, Tavor S, Gourevitch A Eur J Haematol. 2024; 114(2):258-263.

PMID: 39433446 PMC: 11707816. DOI: 10.1111/ejh.14330.

Comparative efficacy and safety of first-line tyrosine kinase inhibitors in chronic myeloid leukemia: a systematic review and network meta-analysis.

Zhang J, Qian Y, Wu Z, Li Y, Guan Y, Sun C Transl Cancer Res. 2024; 13(7):3783-3797.

PMID: 39145083 PMC: 11319984. DOI: 10.21037/tcr-24-747.

Myeloproliferative neoplasm with eosinophilia and coexisting BCR::ABL1 and PDGFRB rearrangement: favorable and rapid response to imatinib.

Yao S, Na L, Liangding H Ann Hematol. 2024; 103(8):3247-3250.

PMID: 38888615 DOI: 10.1007/s00277-024-05832-7.

LncRNA overcomes imatinib resistance in chronic myeloid leukemia via NF-κB/CD44 pathway inhibition.

Wang X, Hou Y, Lyu Y, Zhou J, Zhang X, Hassani M iScience. 2024; 27(6):109851.

PMID: 38784023 PMC: 11112338. DOI: 10.1016/j.isci.2024.109851.

References

Padula W, Larson R, Dusetzina S, Apperley J, Baccarani M, Eigendorff E . Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States. J Natl Cancer Inst. 2016; 108(7). PMC: 4948567. DOI: 10.1093/jnci/djw003. View

Hehlmann R, Heimpel H, Hasford J, Kolb H, Pralle H, Hossfeld D . Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood. 1994; 84(12):4064-77. View

Gratwohl A, Pfirrmann M, Zander A, Kroger N, Beelen D, Novotny J . Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. Leukemia. 2015; 30(3):562-9. PMC: 4777774. DOI: 10.1038/leu.2015.281. View

Hughes T, Lipton J, Spector N, Cervantes F, Pasquini R, Clementino N . Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. Blood. 2014; 124(5):729-36. DOI: 10.1182/blood-2013-12-544015. View

Wang W, Cortes J, Tang G, Khoury J, Wang S, Bueso-Ramos C . Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 2016; 127(22):2742-50. PMC: 4915795. DOI: 10.1182/blood-2016-01-690230. View

Lauseker M, Hanfstein B, Haferlach C, Schnittger S, Pfirrmann M, Fabarius A . Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase. J Cancer Res Clin Oncol. 2014; 140(11):1965-9. DOI: 10.1007/s00432-014-1746-8. View

Cortes J, Gambacorti-Passerini C, Deininger M, Mauro M, Chuah C, Kim D . Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. J Clin Oncol. 2017; 36(3):231-237. PMC: 5966023. DOI: 10.1200/JCO.2017.74.7162. View

Branford S, Fletcher L, Cross N, Muller M, Hochhaus A, Kim D . Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008; 112(8):3330-8. DOI: 10.1182/blood-2008-04-150680. View

Geary C . The story of chronic myeloid leukaemia. Br J Haematol. 2000; 110(1):2-11. DOI: 10.1046/j.1365-2141.2000.02137.x. View

10.

Cortes J, Abruzzese E, Chelysheva E, Guha M, Wallis N, Apperley J . The impact of dasatinib on pregnancy outcomes. Am J Hematol. 2015; 90(12):1111-5. PMC: 5115878. DOI: 10.1002/ajh.24186. View

11.

Cross N . Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Pract Res Clin Haematol. 2009; 22(3):355-65. DOI: 10.1016/j.beha.2009.04.001. View

12.

Gorre M, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao P . Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001; 293(5531):876-80. DOI: 10.1126/science.1062538. View

13.

Islamagic E, Hasic A, Kurtovic S, Suljovic Hadzimesic E, Mehinovic L, Kozaric M . The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2017; 17(4):238-240. DOI: 10.1016/j.clml.2017.02.001. View

14.

Rea D, Nicolini F, Tulliez M, Guilhot F, Guilhot J, Guerci-Bresler A . Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 2016; 129(7):846-854. DOI: 10.1182/blood-2016-09-742205. View

15.

Hochhaus A, Baccarani M, Silver R, Schiffer C, Apperley J, Cervantes F . European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020; 34(4):966-984. PMC: 7214240. DOI: 10.1038/s41375-020-0776-2. View

16.

Johansson B, Fioretos T, Mitelman F . Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 2002; 107(2):76-94. DOI: 10.1159/000046636. View

17.

Fefer A, Buckner C, Thomas E, Cheever M, Clift R, Glucksberg H . Cure of hematologic neoplasia with transplantation of marrow from identical twins. N Engl J Med. 1977; 297(3):146-8. DOI: 10.1056/NEJM197707212970307. View

18.

Buesche G, Ganser A, Schlegelberger B, von Neuhoff N, Gadzicki D, Hecker H . Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia. Leukemia. 2007; 21(12):2420-7. DOI: 10.1038/sj.leu.2404917. View

19.

Chelysheva E, Aleshin S, Polushkina E, Shmakov R, Shokhin I, Chilov G . Breastfeeding in Patients with Chronic Myeloid Leukaemia: Case Series with Measurements of Drug Concentrations in Maternal Milk and Literature Review. Mediterr J Hematol Infect Dis. 2018; 10(1):e2018027. PMC: 5937977. DOI: 10.4084/MJHID.2018.027. View

20.

Nicolini F, Alcazer V, Huguet F, Cony-Makhoul P, Heiblig M, Fort M . CML patients show sperm alterations at diagnosis that are not improved with imatinib treatment. Leuk Res. 2016; 48:80-3. DOI: 10.1016/j.leukres.2016.07.008. View